ICLR241220P330000
- 0.00
- 0.000.00%
Icon PLC Newsroom
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $260
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Icon Analyst Ratings
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
ICON Names Barry Balfe Chief Operating Officer
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $284
Express News | ICON PLC : Truist Securities Cuts Target Price to $284 From $295
Express News | ICON PLC - Appoints Barry Balfe as COO
Express News | ICON Announces Appointment of Chief Operating Officer
The USA healthcare system has long been in collapse! Industry executives: The CEO shooting incident has sounded the alarm for the industry.
① Mark Bertolini, CEO of Oscar Health, believes that the USA healthcare system is considered outdated and ineffective, which has led to a lack of sympathy from the public towards the assassination of Company Executives in the healthcare sector. ② The stock prices in the USA healthcare Industry have already been significantly affected by the shooting incident, and Analyst Jared Holz from Mizuho expects that subsequent uncertainties will continue.
Express News | Form 144 | Icon PLC(ICLR.US) Director Proposes to Sell 3.75 Million in Common Stocks
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
ICON Public Limited Company (ICLR) Fell Along With Peers
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
Nephron Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $280
Nephron Upgrades ICON to Buy, Price Target Is $280
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 48%?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Baird Upgrades Icon PLC(ICLR.US) to Buy Rating, Raises Target Price to $242
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?